Nephros INC Form 4 insider transactions

Arthur H Amron, a Director of Nephros Inc, received 2,418 shares of common stock on August 12, 2026.

Director Arthur H. Amron acquired 3,574 shares of Nephros Inc. common stock in lieu of cash board fees.

Nephros Inc. CEO Robert R. Banks Jr. exercised 120,000 stock options, increasing his direct common stock ownership to 190,000 shares.

Nephros Inc.'s Chief Financial Officer, Judy Krandel, exercised options to acquire 68,861 shares of common stock at $1.71 per share.

Nephros Inc.'s Chief Financial Officer, Judy Krandel, acquired 4,000 stock options with an exercise price of $2.92, vesting over time.

Lisa Marie Nettis, a Director at Nephros Inc., reported the acquisition of 1,622 shares of common stock and provided details on her existing stock options.

NEPHROS Director Oliver Spandow reported the acquisition of 8,036 shares of common stock, increasing his direct beneficial ownership to 122,881 shares.

Nephros Inc. Director Arthur H. Amron reported the acquisition of 5,391 shares of common stock at no cost, increasing his direct beneficial ownership.

Nephros Inc. Director Lisa Nettis was granted 13,229 stock options with an exercise price of $4.49 per share.

Judy Krandel, CFO of Nephros Inc., reports the acquisition of stock options and vesting schedules in a recent SEC filing.

Director Arthur H. Amron reports acquiring and disposing of Nephros Inc. common stock, along with the grant of new stock options.

Director Alisa Lask of Nephros Inc. reported the acquisition of 7,050 stock options on January 1, 2025, as part of her board service compensation.

Director Joseph Michael Harris reports the acquisition of stock options in Nephros Inc. related to his board service.

Director Oliver J. Spandow reports acquisition and disposal of Nephros Inc. common stock and grants of stock options.

Director Arthur H. Amron increased his holdings in Nephros Inc. by purchasing 5,000 shares of common stock in two separate transactions.

Robert R. Banks Jr., CEO of Nephros Inc., recently purchased 50,000 shares of common stock and acquired options to purchase 10,406 shares.

Director Arthur H. Amron reports the acquisition of stock options in Nephros Inc.

Director Alisa Lask reports the acquisition of stock options in Nephros Inc.

Director Oliver J. Spandow reports the acquisition of 7,323 stock options in Nephros Inc.

Director Joseph Michael Harris reports the acquisition of stock options in Nephros Inc.

Wexford Capital LP reports an in-kind distribution of 91,463 shares of Nephros Inc. common stock to Arthur Amron, resulting in a decrease in their direct holdings but maintaining significant indirect ownership.

Director Arthur Amron reports purchasing 7,000 shares of Nephros Inc. and receiving an in-kind distribution of 91,463 shares following separation from Wexford Capital.